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Abstract
Background: Ingrowth of newly formed blood and lymph vessels (angiogenesis) from the limbus region into the
cornea can be treated successfully by subconjunctival application of antiangiogenic agents. Currently, there are
several angiogenesis inhibitors from various manufacturers available, such as vascular endothelial growth factor
(VEGF) antibodies. The aim of the study was to investigate potential cytotoxic effects of two anti-VEGF agents,
ranibizumab (Lucentis®) and bevacizumab (Avastin®) on the human corneal endothelium.
Methods: Human donor corneas, not suitable for corneal transplantation, were organ-cultured in the presence
of either ranibizumab (Lucentis®) or bevacizumab (Avastin®) at different concentrations (group 1: 250 μg / ml,
group 2: 25 μg / ml, group 3: 2.5 μg / ml) for a period of up to 4 weeks. Microscopic imaging for endothelial
cell counting, detection of morphologic alterations of the endothelium, and molecular biology testing (Enzyme-linked
Immunosorbent Assay [ELISA]) for metabolic changes was performed.
Results: Background-corrected results showed neither a significant lactate dehydrogenase (LDH) change with
increasing culturing time nor a significant difference between ranibizumab (Lucentis®) and bevacizumab (Avastin®)
treatment. The endothelial cell density revealed also no statistically significant difference between the two treatment
groups with ranibizumab (Lucentis®) and bevacizumab (Avastin®) at all concentrations tested in this study.
Conclusions: In this study, the anti-angiogenic agents ranibizumab (Lucentis®) and bevacizumab (Avastin®)
demonstrated no cytotoxic effects on the corneal endothelium of human organ-cultured donor corneas
over the limited study time period of 4 weeks. However, based on the study design (in-vitro) and the limited
follow-up period, no conclusions on potential long-term effects can be drawn.
Keywords: Corneal neovascularization, Corneal endothelial cells, Corneal angiogenesis, Vascular endothelial
growth factor, Ranibizumab, Bevacizumab
Background
Antiangiogenic substances have been studied extensively
for their potential cytotoxic effects on human corneal cells
[1–4]. The majority of cell culture and animal studies did
not show any cytotoxic changes of the corneal endothe-
lium in presence of anti-angiogenic agents. However, sin-
gle studies suggest that expression of transmembrane
proteins and Na+/K+ -ATPase may occur under the
influence of antiangiogenic agents, possibly leading to ad-
verse effects on corneal stroma homeostasis [5–7].
Corneal avascularity and transparency are basic prereq-
uisites for the high imaging quality of the human eye.
They are based essentially on the ultrastructure of the cor-
neal stroma and a close interplay of angiogenic and anti-
angiogenic substances. In connection with inflammation,
mechanical or chemical trauma to the cornea; however,
this balance may be disturbed with consecutive ingrowth
of blood and lymph vessels (angiogenesis) from the limbal
region [8, 9]. These changes are usually associated with
decreased corneal transparency and reduction of visual
acuity [10]. Furthermore, corneal neovascularization and
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the associated immunological reactions contribute to
an increased risk of failure and rejection after corneal
transplantation [11–13]. Tang and co-workers showed
that the endothelial growth factor VEGF (vascular
endothelial growth factor) with its isoforms and sur-
face receptors is crucial for the development of cor-
neal neovascularization [14]. VEGF is derived from a
variety of corneal cells, i.e. epithelia, keratocytes and
endothelial cells [15].
Thanks to advances in angiogenesis research in recent
years, specific angiogenesis inhibitors are now available for
topical application [16]. They include VEGF antibodies
such as ranibizumab (Lucentis®) and bevacizumab (Avas-
tin®) as well as anti-angiogenic antisense oligonucleotides.
The long-term goal is to develop a specific dose-re-
sponse curve related to subconjunctival and intracameral
administration of ranibizumab and bevacizumab for pa-
tients at increased risk of rejection after corneal trans-
plantation. The purpose of this study was to evaluate
ranibizumab (Lucentis®) and bevacizumab (Avastin®) for
potential cytotoxic effects on the corneal endothelium of
human in organ-cultured donor corneas.
Methods
Organ cultivation of human donor corneas
All corneas used in this study were taken under the legal
responsibility of the Department of Ophthalmology,
Lions Eye Bank (Federal authority Paul-Ehrlich-Institut:
PEI.G.11601.01.1) within the facilities of the University
Hospital Heidelberg. Forty-six human donor corneas
were included in the study. They were not suitable for
transplantation for one or more of the following reasons:
 Endothelial Cell Count < 2000 Cells/mm2
 Positive Conjunctival Swab
 Positive or Unclear Serology
 Contamination of Fellow Eye
Individual exclusion criteria for each donor cornea are
summarized in Table 1.
In the case of poor quality of the corneas (endothe-
lial cell count < 500 cells per mm2, endothelial cell
necrosis > 50%) or contamination of the culture
medium, the respective test part was stopped and re-
peated with a new cornea.
Table 1 Demographic characteristics of the study samples
ranibizumab (Lucentis®) bevacizumab (Avastin®)
Sex (No. of patient)
Female 9 (37.5%) 11 (50.0%)
Male 15 (62.5%) 11 (50.0%)
Total 24 22
Age, years (No. of patients)
50–59 3 (12.5%) 2 (9.1%)
60–69 4 (16.7%) 7 (31.8%)
70–79 2 (8.3%) 6 (27.3%)
80+ 15 (62.5%) 7 (31.8%)
Mean [Min;Max] 78.7 [51.0;93.8] 73.8 [58.7;88.8]
Causes of death (No. of patients)
Cancer 5 (20.8%) 5 (22.7%)
Cerebrovascular disease 7 (29.2%) 4 (18.2%)
Coronary heart disease 8 (33.3%) 11 (50.0%)
Respiratory diseases 4 (16.7%) 2 (9.1%)
Culture conditions
culture time [d] (Mean [Range]) 23.0 [11.0;42.0] 28.0 [10.0;43.0]
death-to-enucleation-time [h] (Mean [Range]) 26.7 [6.3;49.4] 29.6 [10.9;54.4]
death-to-culture-time [h] (Mean [Range]) 52.2 [10.2;96.9] 61.7 [20.0;138.5]
Reasons for Unsuitability of Donor Corneas
Endothelial Cell Count < 2000 Cells/mm2 4 (16.7%) 5 (22.7%)
Positive Conjunctival Swab 6 (25.0%) 11 (50.0%)
Positive or Unclear Serology 12 (50.0%) 5 (22.7%)
Contamination of Fellow Eye 2 (8.3%) 1 (4.6%)
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Written consent of relatives to use the tissue for scien-
tific purposes was present for all corneas used in this
study.
Corneas included in this study were randomly assigned
to one of 6 study groups or the control group and cul-
tured for 1, 3, 7 or 14 days. Three corneas were used per
time point in each group. The corneas were cut in half
(2 corneas were quartered). One half was used in the
control group and the other half in one of the three
study groups. All corneal segments were cultivated in
48-well plates containing 2 ml of respective liquid (BSS,
medium and agent if any). Study groups contained dif-
ferent concentrations of ranibizumab (Lucentis®) or bev-
acizumab (Avastin®) (group 1: 250 μg / ml, group 2:
25 μg / ml, group 3: 2.5 μg / ml). Study agents were di-
luted in balanced salt solution (BSS). One milliliter of
each dilution was added to 1 ml culture medium (Cor-
nea Max®, Eurobio). In contrast, corneas of the control
group were cultured in 1 ml culture medium supple-
mented with 1 ml of undiluted BSS solution, only.
Determination of endothelial cell count and assessment
of cell morphology
Corneal endothelial cells were qualitatively and quantita-
tively evaluated for abnormalities at baseline using a
specular microscope (EM-3000, Tomey Corporation,
Aichi, Japan). Only corneas with a coefficient of vari-
ation (CV: defined as standard deviation of the cell size
expressed as percentage divided by the mean cell size)
below 40 indicating low polymegathism levels and a hex-
agonality over 50% were used for culturing. Before and
after 1, 3, 7 or 14 days of cultivation all corneas were
stained with 0.06% trypan blue (VisionBlue, D.O.R.C.,
Zuidland, The Netherlands) for evaluation of endothelial
cell viability. In detail, two drops of 0.06% sterile isotonic
trypan blue solution were applied to the corneal speci-
men’s endothelial cells facing up. After incubation for
60 s, corneas were rinsed with balanced salt solution.
Subsequently endothelial cell counting was performed
manually by light microscopy (Olympus CKX41, Olym-
pus Europa Se & Co Kg, Hamburg, Germany). We per-
formed cell counting in real time with the support of the
NAVIS software (NIDEK Technologies Srl, Padova,
Italy). Endothelial cells were counted within a central
rectangle in L-configuration. The endothelial cell count
of the vivid cells was calculated as endothelial cells/mm2
(ECD).
In addition, morphologic parameters such as endo-
thelial cell morphology (cell size and shape) and cell
viability were evaluated at each time point. All cor-
neas were dehydrated for 24 h in a dextran-containing
culture medium (Cornea Jet®, Eurobio) before cell
counting.
Cytotoxicity assay
Endothelial cells were evaluated for potential cell damage
by determination of LDH activity within the culture
medium. LDH is secreted by damaged endothelial cells.
The enzyme is capable of converting the pale yellow test
reagent into red (tetrazolium) which is colorimetrically de-
tectable by a photometer at a wavelength of 490 nm. The
measured light intensity is directly proportional to the
amount of LDH released into the supernatant of the cul-
ture medium [17]. In detail, 96-well microtiter culture
plates were sensitized by incubating with 100 μLVEGF at a
concentration of 0.15mg/L in coating buffer (1mol/L car-
bonate–bicarbonate buffer, pH 9.6) overnight at + 4 °C.
Plates were washed 4-times with PBS containing 0.05%
Tween 20. The remaining unspecific protein-binding sites
were blocked by incubation with 200 μL blocking buffer
(PBS containing 1% BSA) for 2 h at room temperature.
Plates were subsequently washed as follows: After adding
100 μL of 1:100 diluted standards, quality controls (QCs),
or test samples plates were incubated for 1 h at 37 °C in
an iEMS incubator-shaker (Labsystems, Helsinki, Finland)
with a subsequent rinsing. Then, 100 μL of conjugated-
anti IgG antibodies diluted in 1% PBS-BSA was added to
each well for 1 h at room temperature and subsequently
rinsed. Finally, 100 μL o-Phenylenediamine (OPD) (pre-
pared by dissolving tablet sets in 20mL distilled water)
was added and the reaction was allowed to develop at
room temperature in the dark. The color reaction was
stopped by adding 50 μL of 2mol/L sulfuric acid to each
well. Reading was performed at two wavelengths (492 and
620 nm) using an iEMS ELISA plate reader (Labsystems).
The plate background absorbance at 620 nm was sub-
tracted from the absorbance at 492 nm.
Results
Determination of endothelial cell count and assessment
of cell morphology
Corneas showed variable endothelial cell findings in the
study and control groups. Endothelial cell counts did
not shown any statistical significant differences after
treatment with ranibizumab (Lucentis®) and bevacizu-
mab (Avastin®). The overall cell loss and the corneal area
were comparable within study groups (Table 2).
Figure 1 illustrates hexagonal shaped human endothe-
lial corneal cells at a magnification of 10× and 20× ob-
tained by light microscopy. No major differences in
regard to cell morphology (size, shape) and viability were
detected among the study groups and the controls over
time (Fig. 1). No statistical significant endothelial cell
loss occurred during incubation with ranibizumab
(Lucentis®) and bevacizumab (Avastin®) compared to the
control group. A significant natural loss of cells as usu-
ally seen during prolonged incubation in vitro is illus-
trated in the control groups (Fig. 2).
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Cytotoxicity assay
The cytotoxic effect on the endothelial cells was evalu-
ated by photometric determination of the lactate de-
hydrogenase (LDH) enzyme activity in the culture
medium. Under physiologic conditions, the total LDH
concentration in human sera ranges between 0.125 and
0.25 μg / ml. Background-corrected results (Fig. 3 a-c)
show no significant LDH changes in regard to the culti-
vation time as well as any statistically significant differ-
ences among the study groups (ranibizumab (Lucentis®)
versus bevacizumab (Avastin®)) There is only a slight
trend independent from the antiangiogenic concentra-
tion that for bevacizumab (Avastin®) after 7 days and for
ranibizumab (Lucentis®) after 3 days an increase in the
LDH concentration could be observed.
Discussion
The innermost cell layer of the cornea, the corneal
endothelium, plays a key role in maintaining corneal
transparency. As a metabolically active cell assemblage,
they are involved in a continuous outflow of extracellu-
lar fluid from the corneal stroma into the anterior cham-
ber, thus counteracting the constant osmotic gradient of
the protein component of the corneal stroma [18–20].
Preserving of the morphology and functionality of the
corneal endothelium as well as dehydration of the cor-
neal stroma can be permanently impaired by an altered
expression behavior of certain key genes. Inhibition of
the underlying signaling cascade by adequate and early
topical or systemic anti-VEGF therapy plays an import-
ant role in inhibiting corneal angiogenesis and lymph
angiogenesis [21, 22]. The inhibitory effects of bevacizu-
mab on corneal angiogenesis have been demonstrated
previously in various laboratory and animal models. In
addition, an antiangiogenic effect of bevacizumab could
be demonstrated in the context of different anterior eye
segment disorders after topical application, subconjunc-
tival and intracameral administration [22–26].
Experimental studies showed similar inhibitory effects
of topical (eye drops) and subconjunctival administrated
ranibizumab (Lucentis®) [27]. In addition, a non-toxic ef-
fect to the corneal endothelium in patients treated re-
peatedly with intravitreal injections of bevacizumab or
ranibizumab due to age-related macular degeneration
(AMD) is already known [4, 7]. The good tolerability of
Table 2 Clinical Characteristics of the Study Samples
ranibizumab (Lucentis®) bevacizumab (Avastin®)
Endothelial Cell Density ECD [Cells/mm2]
Before Treatment (Mean [Range]) 2441 [1700;3200] 2234 [1700;2800]
After Treatment 0 μg/ml (control) 1847 1644
After Treatment 2.5 μg/ml 1511 1587
After Treatment 25 μg/ml 1460 1417
After Treatment 250 μg/ml 1715 1352
Cell loss 0 μg/ml (control) 18.1% 15.8%
Cell loss 2.5 μg/ml 22.5% 18.0%
Cell loss 25 μg/ml 25.7% 25.8%
Cell loss 250 μg/ml 24.2% 32.5%
Corneal Area [mm2] (Mean) 75.0 67.0
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Fig. 1 Hexagonal shaped single layer human endothelial corneal cells
of donor corneas before (a, c, e, g) and after (b, d, f, h) incubation with
250 μg/ml ranibizumab (Lucentis®) or bevacizumab (Avastin®) at
indicated magnifications. No statistical significant difference between
before and after could be detected
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Fig. 2 Endothelial cell density (mm2) before (blue) and after (red) incubation with ranibizumab (Lucentis®) or bevacizumab (Avastin®)
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Fig. 3 Overview of measurements of LDH values as a function of culture time a: LDH values for 0–250 μg / ml ranibizumab (Lucentis®) b: LDH
values for 0–250 μg/ml bevacizumab (Avastin®); c: LDH values for ranibizumab (Lucentis®) or bevacizumab (Avastin®) after background correction
with 0 μg/ml control group
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both antiangiogenic substances could be confirmed in
our in vitro laboratory study on human corneal endothe-
lial cells. Since the effects of ranibizumab and bevacizu-
mab on human corneal endothelial cells have currently
only been investigated secondary to intravitreal injec-
tions inpatients with age-related AMD and in cell cul-
ture models it is of particular interest to analyze the
potential influence of both substances on the corneal
endothelium after topical (eye drop), subconjunctival
and intracameral application [7, 28] .
In addition, the safety and toxicity of ranibizumab and
bevacizumab has only performed in endothelial cell cul-
ture or animal models. Studies on human donor corneas
are lacking. Best of our knowledge, the present study
was the first laboratory investigation demonstrating that
both anti-angiogenic substances – ranibizumab and bev-
acizumab – did not show cytotoxic effects on the human
endothelium in corneal donor tissue. Cell culture models
using human retinal pigment epithelium (ARPE-19) cells
were able to confirm out findings with no toxic effect
after single or repeated application of various doses of
VEGF antagonists under normal and oxidative stress
[29]. In addition, Aflibercept did not show any negative
effects on retinal cell lines at all [30]. Also bevacizumab
might potentially affect mitochondria functionality dif-
ferently from ranibizumab and aflibercept, ranibizumab
and aflibercept at clinical doses protect against cytotox-
icity in human ARPE-19 cells [31]. It could even been
excluded that normal doses of ranibizumab and afliber-
cept produce mitochondrial toxicity or cell death. How-
ever, bevacizumab and ziv-aflibercept are proven to have
mild mitochondrial toxicity at clinically relevant doses in
ARPE-19 cells [32]. Additionally studies indicate that
anti-VEGF agents can interfere with the physiological
functions of RPE cells under high-glucose conditions
leading to decrease in cell viability and proliferation [33].
There is moderate evidence that ranibizumab and bev-
acizumab are equivalent in terms of efficacy and toxicity
[34]. Additionally, ranibizumab and aflibercept showed a
similar endophthalmitis rates after intravitreal applica-
tion compared to bevacizumab [35]. In general, intraoc-
ular application of low doses of VEGF does not induce
irreversible toxic retinal damage [36]. Furthermore it
was stated that aflibercept and ranibizumab are more
effective than bevacizumab against type 1 choroidal neo-
vascularization because of the lower amount of VEGF in
the posterior chamber using aflibercept and ranibizumab
compared to bevacizumab [37].
No differences in overall safety between the three anti-
angiogenic drugs that are currently available but results
are imprecise for cardiovascular events and death [38].
Therefore, storage of antiangiogenics within cells of in-
traocular tissues as observed in vivo after intravitreal in-
jection into monkey eyes, may result in unknown side
effects during long-term treatment of patients. Only the
antibody bevacizumab (not the antibody fragment rani-
bizumab) was shown to accumulate in both retinal
endothelial cells and pigment epithelial cells during pro-
longed treatment. This might be of importance because
patients are often treated for several years and so add-
itional long-term side effects may be realized in the
future [39, 40].
Therefore, key gene expression assays should contrib-
ute to a better understanding of possible long-term ef-
fects of anti-VEGF therapy on the functional properties
of corneal endothelial cells. It may also be possible to re-
duce the risk of rejection following corneal transplant-
ation in the future by supplementing gene therapy. The
identification of new key genes would make a corre-
sponding contribution to this. The results of our study
showed that there were no statistically significant cyto-
toxic effects of ranibizumab and bevacizumab on the
human endothelial cells at various concentrations.
Conclusions
In this short time study, no cytotoxic effects of either
ranibizumab (Lucentis®) or bevacizumab (Avastin®) on
the corneal endothelium of human organ-cultured
donor corneas were observed. After deducting the con-
trol group, neither a significant increase in LDH expres-
sion nor a significant difference between ranibizumab
(Lucentis®) and bevacizumab (Avastin®) incubation could
be detected. Within the 4 weeks of incubation there was
no statistically significant higher endothelial cell loss
during incubation with ranibizumab (Lucentis®) and bev-
acizumab (Avastin®). There were no obvious morpho-
logical differences between the two study groups over
time and compared to their respective controls indicat-
ing no difference in cytotoxicity between ranibizumab
(Lucentis®) and bevacizumab (Avastin®).
As a serious limitation of this study it has to be em-
phasized that all conclusions are based on a study time
of only 4 weeks. Negative effects occurring after pro-
longed incubation time can therefore not be excluded.
Abbreviations
AMD: Age-related macular degeneration; BSA: Bovine serum albumin;
BSS: Balanced salt solution; ELISA: Enzyme-linked immunosorbent assay;
LDH: Lactate dehydrogenase; OPD: Ortho-phenylenediamine; PBS: Phosphate
buffered solution; VEGF: Vascular endothelial growth factor
Acknowledgements
Many thanks to Irina Vöhringer and Brigitte Erber for their great help in
conducting all the experiments. We acknowledge financial support by
Deutsche Forschungsgemeinschaft within the funding program Open
Access Publishing, by the Baden-Württemberg Ministry of Science, Research
and the Arts and by Ruprecht-Karls-Universität Heidelberg.
Funding
Study sponsored by Novartis Pharma GmbH. Novartis sponsored the study
but was not actively involved in designing or performing this investigator
initiated trial study. Design of the study, collection, analysis, and
Merz et al. BMC Ophthalmology          (2018) 18:316 Page 6 of 8
interpretation of data as well as writing the manuscript was performed
independent from Novartis at the University Hospital Heidelberg. Novartis
granted publication of data.
Availability of data and materials
The datasets used and/or analyzed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
PRM analyzed and interpreted the patient data and was a major contributor
in writing the manuscript. NR, SB and IS designed the study, performed the
examinations, analyzed and interpreted the patient data and revised the
manuscript. GUA and IS were major contributors in writing the manuscript.
All authors read and approved the final manuscript.
Ethics approval and consent to participate
The study was approved by the Ethikkommission Heidelberg, Germany
under the reference number S-318 / 2012. Informed consent was obtained
for each donor prior to participation in the study. All procedures conformed
to HIPAA regulations and the Declaration of Helsinki for research involving
human subjects.
Consent for publication
Not applicable.
Competing interests
GUA received research grants from Novartis Pharma GmbH. The other
authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1Department of Ophthalmology, University of Heidelberg, Lions Eye Bank, Im
Neuenheimer Feld 400, 69120 Heidelberg, Germany. 2Department of
Ophthalmology, Goethe-University Frankfurt, Theodor-Stern-Kai 7, 60590
Frankfurt/Main, Germany.
Received: 28 June 2018 Accepted: 27 November 2018
References
1. Yoeruek E, Spitzer MS, Tatar O, Aisenbrey S, Bartz-Schmidt KU, Szurman P.
Safety profile of bevacizumab on cultured human corneal cells. Cornea.
2007;26:977–82.
2. Chalam KV, Agarwal S, Brar VS, Murthy RK, Sharma RK. Evaluation of
cytotoxic effects of bevacizumab on human corneal cells. Cornea. 2009;28:
328–33.
3. Park HY, Kim SJ, Lee HB, Kim ES, Tchah H. Effect of intracameral
bevacizumab injection on corneal endothelium in rabbits. Cornea. 2008;27:
1151–5.
4. Chiang CC, Chen WL, Lin JM, Tsai YY. Effect of bevacizumab on human
corneal endothelial cells: a six-month follow-up study. Am J Ophthalmol.
2008;146:688–91.
5. Ambati BK, Nozaki M, Singh N, Takeda A, Jani PD, Suthar T, Albuquerque RJ,
Richter E, Sakurai E, Newcomb MT, Kleinman ME, Caldwell RB, Lin Q, Ogura
Y, Orecchia A, Samuelson DA, Agnew DW, St Leger J, Green WR,
Mahasreshti PJ, Curiel DT, Kwan D, Marsh H, Ikeda S, Leiper LJ, Collinson JM,
Bogdanovich S, Khurana TS, Shibuya M, Baldwin ME, Ferrara N, Gerber HP,
De Falco S, Witta J, Baffi JZ, Raisler BJ, Ambati J. Corneal avascularity is due
to soluble VEGF receptor-1. Nature. 2006;443:993–7.
6. Yoeruek E, Tatar O, Spitzer MS, Saygili O, Biedermann T, Bartz-Schmidt KU,
Thaler S, Szurman P. Effects of bevacizumab on apoptosis, Na+ -K+
−adenosine triphosphatase and zonula occludens 1 expression on cultured
corneal endothelial cells. Ophthalmic Res. 2010;44:43–9.
7. Pérez-Rico C, Benítez-Herreros J, Castro-Rebollo M, Gómez-Sangil Y, Germain
F, Montes-Mollón MA, Teus MA. Effect of intravitreal ranibizumab on corneal
endothelium in age-related macular degeneration. Cornea. 2010;29:849–52.
8. Cursiefen C, Seitz B, Dana MR, Streilein JW. Angiogenese und
Lymphangiogenese in der Hornhaut. Pathogenese, Klinik und
Therapieoptionen Ophthalmologe. 2003;100:292–9.
9. Zheng Y, Lin H, Ling S. Clinicopathological correlation analysis of (lymph)
angiogenesis and corneal graft rejection. Mol Vis. 2011;17:1694–700.
10. Whitcher JP, Srinivasan M, Upadhyay MP. Corneal blindness: a global
perspective. Bull World Health Organ. 2001;79(3):214–21.
11. Cursiefen C, Chen L, Dana MR, Streilein JW. Corneal lymphangiogenesis:
evidence, mechanisms, and implications for corneal transplant immunology.
Cornea. 2003;22:273–81.
12. Bachmann B, König Y, Hos D, Parthasarathy A, Cursiefen C. Topical inhibition
of angiogenesis at the cornea. Safety and efficacy Ophthalmologe. 2009;
106:399–406.
13. Qazi Y, Wong G, Monson B, Stringham J, Ambati BK. Corneal transparency:
genesis, maintenance and dysfunction. Brain Res Bull. 2010;81:198–210.
14. Tang XL, Sun JF, Wang XY, Du LL, Liu P. Blocking neuropilin-2 enhances
corneal allograft survival by selectively inhibiting lymphangiogenesis on
vascularized beds. Mol Vis. 2010;16:2354–61.
15. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth
factor and its receptors in inflamed and vascularized human corneas. Invest
Ophthalmol Vis Sci. 2000;41:2514–22.
16. Ziemssen F, Heiduschka P, Peters S, Grisanti S, Schraermeyer U. Chances and
risks of anti-VEGF therapy. Klin Monatsbl Augenheilkd. 2008;225:770–8.
17. Szekeres J, Pacsa AS, Pejtsik B. Measurement of lymphocyte cytotoxicity by
assessing endogenous alkaline phosphatase activity of the target cells.
J Immunol Methods. 1981;40(2):151–4.
18. Jones RF, Maurice DM. New methods of measuring the rate of aqueous
flow in man with fluorescein. Exp Eye Res. 1966;5:208–20.
19. Carlson KH, Bourne WM, McLaren JW, Brubaker RF. Variations in human
corneal endothelial cell morphology and permeability to fluorescein with
age. Exp Eye Res. 1988;47:27–41.
20. Bourne WM. Clinical estimation of corneal endothelial pump function. Trans
Am Ophthalmol Soc. 1998;96:229–39.
21. Han YS, Lee JE, Jung JW, Lee JS. Inhibitory effects of bevacizumab on
angiogenesis and corneal neovascularization. Graefes Arch Clin Exp
Ophthalmol. 2009;247:541–8.
22. Hosseini H, Nowroozzadeh MH, Salouti R, Nejabat M. Anti-VEGF therapy with
bevacizumab for anterior segment eye disease. Cornea. 2012;31:322–34.
23. Benayoun Y, Adenis JP, Casse G, Forte R, Robert PY. Effects of
subconjunctival bevacizumab on corneal neovascularization: results of a
prospective study. Cornea. 2012;31(8):937–44.
24. Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, Zahn G, Cursiefen
C. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and
lymphangiogenesis. Invest Ophthalmol Vis Sci. 2007;48:2545–52.
25. Hos D, Horn F, Martus P, Cursiefen C. Improved semiautomatic method for
morphometry of angiogenesis and lymphangiogenesis in corneal
flatmounts. Exp Eye Res. 2008;87:462–70.
26. Dastjerdi MH, Saban DR, Okanobo A, Nallasamy N, Sadrai Z, Chauhan SK,
Hajrasouliha AR, Dana R. Effects of topical and subconjunctival bevacizumab
in high-risk corneal transplant survival. Invest Ophthalmol Vis Sci. 2010;51:
2411–7.
27. Sener E, Yuksel N, Yildiz DK, Yilmaz B, Ozdemir O, Caglar Y, Degirmenci E.
The impact of subconjuctivally injected EGF and VEGF inhibitors on
experimental corneal neovascularization in rat model. Curr Eye Res. 2011;
36(11):1005–13.
28. Benítez-Herreros J, Pérez-Rico C, Teus MA, Gómez-San Gil Y, Castro-Rebollo
M. Morphometric analysis of corneal endothelium after intravitreal
ranibizumab (Lucentis) in age-related macular degeneration treatment. Arch
Soc Esp Oftalmol. 2010;85(10):329–32.
29. Saenz-de-Viteri M, Fernández-Robredo P, Hernández M, Bezunartea J, Reiter
N, Recalde S, García-Layana A. Single- and repeated-dose toxicity study of
bevacizumab, ranibizumab, and aflibercept in ARPE-19 cells under normal
and oxidative stress conditions. Biochem Pharmacol. 2016;103:129–39.
30. Schnichels S, Hagemann U, Januschowski K, Hofmann J, Bartz-Schmidt KU,
Szurman P, Spitzer MS, Aisenbrey S. Comparative toxicity and proliferation
testing of aflibercept, bevacizumab and ranibizumab on different ocular
cells. Br J Ophthalmol. 2013;97(7):917–23.
31. Sheu SJ, Chao YM, Liu NC, Chan JY. Differential effects of bevacizumab,
ranibizumab and aflibercept on cell viability, phagocytosis and
mitochondrial bioenergetics of retinal pigment epithelial cell. Acta
Ophthalmol. 2015;93(8):e631–43.
Merz et al. BMC Ophthalmology          (2018) 18:316 Page 7 of 8
32. Malik D, Tarek M, Caceres del Carpio J, Ramirez C, Boyer D, Kenney MC,
Kuppermann BD. Safety profiles of anti-VEGF drugs: bevacizumab,
ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment
epithelium cells in culture. Br J Ophthalmol. 2014;98(Suppl 1):i11–6.
33. Oh JR, Han JW, Kim YK, Ohn YH, Park TK. The effects of anti-vascular
endothelial growth factor agents on human retinal pigment epithelial cells
under high glucose conditions. Int J Ophthalmol. 2017;10(2):203–10.
34. Zhu Y, Zhang T, Xu G, Peng L. Anti-vascular endothelial growth factor for
choroidal neovascularization in people with pathological myopia. Cochrane
Database Syst Rev. 2016;12:CD011160.
35. Forooghian F, Albiani DA, Kirker AW, Merkur AB. Comparison of endophthalmitis
rates following intravitreal injection of compounded bevacizumab, ranibizumab,
and aflibercept. Can J Ophthalmol. 2017;52(6):616–9.
36. Januschowski K, Schnichels S, Hagemann U, Koch V, Hofmann J, Spitzer MS,
Bartz-Schmidt KU, Szurman P, Lüke M, Aisenbrey S. Electrophysiological
toxicity testing of VEGF trap-eye in an isolated perfused vertebrate retina
organ culture model. Acta Ophthalmol. 2014;92(4):e305–11.
37. Yoshihara N, Terasaki H, Shirasawa M, Kawano H, Sonoda S, Yamaguchi M,
Hashiguchi T, Hisatomi T, Ishibashi T, Sakamoto T. Permeability and anti-
vascular endothelial growth factor effects of bevacizumab, ranibizumab, and
aflibercept in polarized retinal pigment epithelial layer in vitro. Retina. 2017;
37(1):179–90.
38. Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti-vascular
endothelial growth factor for diabetic macular edema: a network meta-
analysis. Cochrane Database Syst Rev. 2017;6:CD007419.
39. Lang GE, Lang GK, Deissler HL. Basic in vitro studies on VEGF inhibition with
aflibercept: similarities and differences to other VEGF-binding therapeutic
proteins. Klin Monatsbl Augenheilkd. 2015;232(3):295–302.
40. Lang GE, Lang GK, Deissler HL. Treatment of diabetic macular edema with
the VEGF inhibitors ranibizumab and bevacizumab: conclusions from basic
in vitro studies. Klin Monatsbl Augenheilkd. 2014;231(5):527–34.
Merz et al. BMC Ophthalmology          (2018) 18:316 Page 8 of 8
